Evidence map›Paper›PMID 36809256›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2023

Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score.

Marianna Adamo, Antonio Popolo Rubbio, Gregorio Zaccone, Michele Pighi, Mauro Massussi, Daniela Tomasoni, Edoardo Pancaldi, Luca Testa, Maurizio B Tusa, Federico De Marco and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Expanding the boundaries of M-TEER: is it time to treat moderate secondary mitral regurgitation?EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
  3. Review
  4. 2024 update in heart failure.ESC heart failure · 2025
    Review
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Marianna AdamoCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Antonio Popolo RubbioDepartment of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Gregorio ZacconeCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Michele PighiDivision of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Mauro MassussiCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Daniela TomasoniCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Edoardo PancaldiCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Luca TestaDepartment of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Maurizio B TusaDepartment of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Federico De MarcoCentro Cardiologico Monzino, IRCCS, Milan, Italy.
Cristina GianniniCardiac Catheterization Laboratory, Cardiothoracic and Vascular Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Carmelo GrassoDivision of Cardiology, Centro Alte Specialità e Trapianti (CAST), Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele, University of Catania, Catania, Italy.
Francesco De FeliceDivision of Interventional Cardiology, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy.
Paolo DentiCardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
Cosmo GodinoCardio-Thoracic-Vascular Department, San Raffaele University Hospital, Milan, Italy.
Annalisa MongiardoDivision of Cardiology, University Magna Graecia, Catanzaro, Italy.
Gabriele CrimiCardiology Unit, Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino Genoa, Genova, Italy.
Emmanuel VillaCardiac Surgery Unit and Transcatheter Valve Therapy Group, Poliambulanza Foundation Hospital, Brescia, Italy.
Ida MonteforteAORN Ospedali dei Colli, Monaldi Hospital, Naples, Italy.
Rodolfo CitroUniversity Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
Arturo GiordanoInvasive Cardiology Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy.
Antonio L BartorelliCentro Cardiologico Monzino, IRCCS, Milan, Italy.
Anna Sonia PetronioCardiac Catheterization Laboratory, Cardiothoracic and Vascular Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Giuliano ChizzolaCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Giuseppe TarantiniDepartment of Cardiac, Thoracic and Vascular Science, Interventional Cardiology Unit, University of Padua, Padua, Italy.
Corrado TamburinoDivision of Cardiology, Centro Alte Specialità e Trapianti (CAST), Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele, University of Catania, Catania, Italy.
Francesco BedogniDepartment of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Marco MetraCardiology and Cardiac catheterization laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA risk score was recently derived from the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial. However, external validation of this score is still lacking.

aimsWe aimed to validate the COAPT risk score in a large multicentre population undergoing mitral transcatheter edge-to-edge repair (M-TEER) for secondary mitral regurgitation (SMR).

methodsThe Italian Society of Interventional Cardiology (GIse) Registry of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO) population was stratified according to COAPT score quartiles. The performance of the COAPT score for 2-year all-cause death or heart failure (HF) hospitalisation was evaluated in the overall population and in patients with or without a COAPT-like profile.

resultsAmong the 1,659 patients included in the GIOTTO registry, 934 had SMR and complete data for a COAPT risk score calculation. The incidence of 2-year all-cause death or HF hospitalisation progressively increased through the COAPT score quartiles in the overall population (26.4% vs 44.5% vs 49.4% vs 59.7%; log-rank p<0.001) and COAPT-like patients (24.7% vs 32.4% vs 52.3% vs. 53.4%; log-rank p=0.004), but not in those with a non-COAPT-like profile. The COAPT risk score had poor discrimination and good calibration in the overall population, moderate discrimination and good calibration in COAPT-like patients and very poor discrimination and poor calibration in non-COAPT-like patients.

conclusionsThe COAPT risk score has a poor performance in the prognostic stratification of real-world patients undergoing M-TEER. However, after application to patients with a COAPT-like profile, moderate discrimination and good calibration were observed.

Indexed as

Heart FailureHeart Valve Prosthesis ImplantationMitral Valve InsufficiencyHospitalizationHumansRisk FactorsTreatment Outcome

Identifiers

PMID36809256
PMCPMC10111134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.